Phenothiazines interfere with dopaminergic neurodegeneration in Caenorhabditis elegans models of Parkinson's disease.
Oxidative stress is involved in the pathogenesis of various neurodegenerative disorders, conventional antioxidant strategies have yet been of limited success. We have employed transgenic Caenorhabditis elegans expressing DsRed2 in dopaminergic neurons and CFP pan-neuronally, to characterize in larval and adult animals the effects of rotenone and 1-methyl-4-phenyl-pyridinium (MPP(+)) on the dopaminergic system. Investigating the antioxidant phenothiazine and different derived antipsychotic drugs, it was found that free phenothiazine exerted strong neuroprotection at the cellular level and resulted in a better performance in behavioral assays, whereas apomorphine and other dopamine agonists only rescued adult locomotor parameters. Phenothiazine antipsychotics with dopamine antagonist properties were likewise not cytoprotective, but even induced motor deficits by themselves. Beyond phenothiazine, other tricyclic imines elicited significant neuroprotection at considerably lower doses than different natural antioxidants. Mitochondrially targeted antioxidants were more potent than these untargeted natural antioxidants, yet not as potent as the untargeted compound phenothiazine. Thus, dopaminergic toxicity of rotenone and MPP(+)in vivo can be forestalled by nanomolar concentrations of certain chain-breaking antioxidants irrespective of dopamine receptor modulation or mitochondrial targeting.
Mocko
Justyna B
JB
Department of Pathobiochemistry, University Medical Center of the Johannes Gutenberg University, Duesbergweg 6, 55099 Mainz, Germany.
Kern
Andreas
A
Moosmann
Bernd
B
Behl
Christian
C
Hajieva
Parvana
P
D000818:Animals; D030801:Animals, Genetically Modified; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D017173:Caenorhabditis elegans / Q000235:genetics*; D004195:Disease Models, Animal; D004298:Dopamine / Q000502:physiology*; D006801:Humans; D007306:Insecticides / Q000633:toxicity; D008957:Models, Genetic; D009410:Nerve Degeneration / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D020734:Parkinsonian Disorders / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D010640:Phenothiazines / Q000494:pharmacology* / Q000627:therapeutic use; D012402:Rotenone / Q000633:toxicity
D014150:Antipsychotic Agents; D007306:Insecticides; D018696:Neuroprotective Agents; D010640:Phenothiazines; D012402:Rotenone; D004298:Dopamine